A ntibiotic-resistant bacterial infections pose a serious threat to public health, and there is an ongoing need for a pipeline of new antibacterial agents (1, 2) . Compounds that have novel chemical structures or inhibit new targets in essential biosynthetic pathways are of particular interest because they are not expected to be susceptible to resistance mechanisms already established for other antibiotics. Moenomycin A (1, Figure 1 , MmA) (3) is a natural product antibiotic that may serve as a promising lead for new antibiotics because it combines a novel structure with a unique mechanism of action. It inhibits peptidoglycan glycosyltransferases (PGTs), the enzymes that make the carbohydrate chains of bacterial peptidoglycan (PG) (4) . Peptidoglycan biosynthesis is a major target for clinically used antibiotics, most of which are derived from natural products. Moenomycin is the only known natural product that directly inhibits the PGTs, and it provides a blueprint to guide the design of potent, broadspectrum inhibitors to this family of antibiotic targets.
The biological activity of moenomycin is remarkable compared with that of most other natural product antibiotics: it is 10Ϫ1000 times more potent than vancomycin (5, 6) against Gram-positive organisms, with MICs below 0.1 g mL
Ϫ1
. It was developed for use as a growth promoter in animals, but its use in humans has been prevented by its poor physicochemical properties. Altering these properties has long been a goal. In a beautiful series of papers in the 1980s and 1990s, Welzel and co-workers used chemical synthesis to make a wide range of moenomycin analogues and elucidated several critical features of moenomycin that are essential for activity (3) ; however, a lack of detailed structural information on how moenomycin binds to its PGT targets eventually impeded progress in analogue design. In the past 3 years, crystal structures of moenomycins bound to four different peptidoglycan glycosyltransferases have provided structural information to guide the design of new analogues. As is common, however, there are differences among the four complexes in the detailed contacts between the proteins and the ligands.
The most significant differences involve how the phosphoglycerate unit binds because these differences raise questions about the importance of the phosphoglycerate (7−10) . We have used chemical synthesis combined with structural analysis to address its role, with particular emphasis on the carboxylate moiety. The importance of carboxylate of moenomycin in target binding has not been systematically explored previously, and there are notable differences among the crystal structures with respect to the protein contacts to this carboxylate. In one of the complexes, Staphylococcus aureus PBP2 (Figure 2, panel d) , a conserved negatively charged glutamate side chain makes a proposed contact to the carboxylate, possibly via a bridging hydrogen bond (9) . In another complex, Escherichia coli PBP1B, there are no side chains within 4 Å of the carboxylate (8) . In the other two complexes, Aquifex aeolicus PBP1A and S. aureus MGT (Figure 2 , panels b and e), an invariant lysine side chain is proposed to anchor the carboxylate (7, 10) . The differences in the four PGT complexes raised questions about whether the carboxylate is critical for binding, and if so, whether the negative charge or the hydrogen bonding capability of the carboxyl group is more important. We have used a degradationreconstruction approach to make six MmA analogues to address the role of the phosphoglycerate moiety of moenomycin in binding to peptidoglycan glycosyltransferases (11) . We report here the multistep synthesis of these compounds, their biological evaluation, and modeling studies restrained by crystallographic data for cocomplexes of two of the compounds. Our analysis indicates that the carboxylate plays a central role in binding to the target through energetically favorable ionic interactions with positively charged side chains in the active site. These interactions help orient the lipid chain for binding along the hydrophobic groove that funnels down from the active site to the membrane.
RESULTS AND DISCUSSION
Synthesis of MmA Analogues. In 2006 we reported the total synthesis of moenomycin as well as chemistry to degrade and reconstruct this natural product (11, 12) . The latter chemistry allows us to independently change the phosphoryl group, the carboxylate, or the lipid of the phosphoglycerate moiety. Both these groups have previously been implicated in target binding (13) , but the role of the carboxylate has not been explored in detail.
Here we report the preparation of six derivatives of MmA in which individual features of the phosphoglycerate have been systematically varied. Two series of moenomycin compounds were prepared, one containing the natural C25 isoprenyl chain (3 and 4, Figure 3 ) and the other containing a neryl (C10) chain (5 and 6, Figure 3 ). In each series we synthesized one derivative in which the phosphoryl group was capped (3 and 5, Figure 3 ) and another in which the carboxylate was removed (4 and 6, Figure 3 ). In the C10 series, we also synthesized the isosteric carboxamide analogue 7 (Figure 3) , which maintains the hydrogen-bonding network available to the carboxylate but removes the charge, and the acylsulfonamide analogue 34 (Scheme 3), which maintains the charge. The synthesis of each analogue required approximately 14 steps, and the combined syntheses of six different analogues highlights the utility of the synthetic methods we previously developed to degrade and reconstruct analogues of this densely functionalized natural product.
The desired phosphoglycerate derivatives were obtained by first preparing the appropriate lipid glycerates (Scheme 1). Briefly, alcohols 8 and 9 were prepared by coupling allyl bromides 11 (11) and 12 to the monotriisopropylsilyl protected ethylene glycol 13 followed by deprotection with TBAF. Alcohol 10 was prepared by amidation of carboxylic acid 16 (11) , prepared from glycidol in six steps, followed by deprotection with DDQ. To obtain the desired phosphodiesters 22Ϫ25, the C25-lipid-containing alcohol 8 and the C10- lipid-containing alcohols 9, 10, and 18 were subjected to condensation with the core pentasaccharide H-phosphonate 21 (Scheme 2), which was prepared from MmA (1) (11) . Competing esterification of alcohols 9 and 10 by 1-adamantanecarbonyl chloride (14) can be suppressed if addition of the 1-adamantanecarbonyl chloride is added as a solution in pyridine at 0°C. Treatment with carbon tetrachloride (15, 16) effects in situ oxidation to form the corresponding phosphodiesters 22Ϫ25 selectively without affecting other chemically sensitive functionality (e.g., the 2-amino-1,3-cyclopentadione of the A-ring and olefins within the isoprenoid chain). Subsequent saponification of the phosphodiesters 22Ϫ24 afforded the phosphoglycols 4 and 6 and the phosphoglyceramide 7 in satisfactory yield (Scheme 2 and Figure 3 ). Methyl phosphates 3 and 5 ( Figure 3 ) were prepared by selective hydrolysis of methyl esters 19 and 26 under alkaline conditions (Scheme 2). Hydrolysis of the methyl phosphate was not observed under these reaction conditions.
The desired acylsulfonamide 34 (Scheme 3) was prepared by coupling the pentasaccharide lactol 20 with the protected acylsulfonamide 31. Our route to the protected acylsulfonamide 31 is patterned on a synthetic route developed by Welzel (17, 18) . The carboxylic acid 29 was prepared in two steps from known 1,3: (27) (19−21) . Condensation of 29 with N-allyl-methanesulfonamide (22) was achieved under mild conditions using DCC in the presence of a stoichiometric amount of DMAP to afford optically pure N-allyl-protected acylsulfonamide 30. An allyl group was chosen to protect the acylsulfonamide so that it could be selectively removed under neutral conditions (e.g., palladium catalysis) (23, 24) . Acid hydrolysis of the silyl ether 30 gave the primary alcohol 31, which was used for coupling with the protected pentasaccharide 20. The phosphoramidite was prepared in situ from 31, coupled with lactol 20, and further oxidized with tert-butylhydroperoxide to give phosphotriester 32. The use of the phosphoramidite coupling (25−28) to prepare 32 turned out to be a more effective procedure than the H-phosphonate coupling method (26, 29) used to prepare compounds 2 and 4-7. The phosphoramidite coupling method avoids transformation of lactol 20 to H-phosphonate 21 and the potential to competitively acylate 31. To deprotect the acylsulfonamide 32, a few allyl scavengers were tested (morpholine (30) , p-toluenesulfinate (31) , and barbituric acid (32)). Barbituric acid successfully removed the allyl group from 32 under palladium catalysis to give free acylsulfonamide 33. These conditions for allyl group deprotection did not decompose the chemically labile allylic ether of the isoprenoid chain (33) . As far as we know, this is the first report of the use of an allyl group to protect an acylsulfonamide. The final global deprotection of 33 in mild base afforded the acylsulfonamide 34 (Scheme 3).
Evaluation of Biological Activity of MmA Analogues. We first evaluated the ability of the moenocinyl analogues 3 and 4 to inhibit the PGT activity of PBP2 from S. aureus (34, 35) and PBP2A from E. faecalis (11) using a previously described PGT assay (36, 37) . The inhibitory ability of an analogue is reported as the half maximal inhibitory concentration (IC 50 ), the concentration at which the analogue inhibits 50% of the Lipid II polymerization activity catalyzed by PGTs. Polymerization activity was monitored by paper chromatography using a radiolabeled synthetic Lipid II substrate. We also determined the minimum inhibitory concentrations (MICs) of compounds 3 and 4 against laboratory strains of S. aureus and E. faecalis (Table 1 ). The MICs of analogues 3 and 4 were 5Ϫ10 and ϳ25 times higher, respectively, than that of MmA; however, the increased MICs were not reflected in the IC 50 values for the analogues, which are similar to those for MmA (Table 1) . One explanation for this observation is that the long moenocinyl chain interacts so strongly with the purified enzymes via nonspecific hydrophobic interactions that the effects of changes elsewhere in the molecule are obscured. That is, the in vitro assay may be not capable of distinguishing activity differences among compounds with low nanomolar binding since the enzyme is stoichiometrically inhibited. We prepared the corresponding neryl analogues 5 and 6 to probe the importance of the phosphoryl group and carboxylate in the context of a molecule that does not bind to the target as tightly. We have previously shown that neryl analogue 2 (11), although it has no biological activity, has very good enzyme inhibitory activity (10-fold lower than that of the natural product in our assay); furthermore, it binds in the same region of the active site as MmA itself and establishes similar contacts. Therefore, it is a good model system for assessing the importance of particular proteinϪligand contacts. The IC 50 values of analogues 5 and 6 were 2 orders of magnitude higher than that of 2, showing that both the phosphoryl group and the carboxylate make critical contacts to the target (7). The magnitude of the change in binding for 5 and 6 are in the range that might be expected for an electrostatic contact between a ligand and a protein (38, 39) . In all four reported moenomycin:PGT structures, the phosphoryl group makes a similar network of contacts to charged residues. These contacts likely explain the diminished affinity of 5 compared with 2, as reflected in the IC 50 values. However, the contacts to the carboxylate in the reported crystal structures vary (see the introduction). Therefore, although the lack of activity of the descarboxyl analogue highlights the importance of the carboxylate, we had to carry out further experiments to determine the structural basis for requiring this functional group. To determine whether the hydrogen bonding network or the negative charge is most important for binding, we prepared carboxamide 7, an uncharged isostere of 2 that is capable of hydrogen binding, and the acylsulfonamide analogue 34. Acylsulfonamides are known to be fully deprotonated at physiological pH (pK a ϳ4Ϫ5) (40) and are often used to mimic carboxylate groups. Although the acylsulfonamide is sterically larger than the carboxylate functionality, analysis of the X-ray structures of the complexes suggested there might be sufficient room for this group. Compound 7 was found to have an IC 50 value comparable to that of the descarboxyl analogue against both PGTs tested; the IC 50 of the acylsulfonamide analogue 34 was 5Ϫ10 fold better than that of the carboxamide isostere 7. These results are consistent with the hypothesis that a negative charge in this region of MmA plays a key role in binding. The increased steric hindrance of the sulfonamide group may explain the observation that 34 is not as potent an inhibitor as 2. Nevertheless, the activity of the analogue demonstrates that it is possible to make significant changes to this portion of the molecule provided the negative charge is maintained.
Computational Analysis of n-MmA Analogues Complexed with the aaPGT Domain. We attempted to obtain X-ray structural data on 5 and 6 complexed to aaPGT domain but were only partially successful. Although data sets were acquired for complexes with both ligands, the fractional occupancy was low. The positions of the phosphoryl groups were clear, but the density of the other parts was not as good. Therefore, we used molecular modeling to help rationalize the effects of the structural changes on binding for the analogues in Figure 3 . Docking computations of moenomycin analogues were performed with LigPrep and Glide from the Schrödinger Suite using the X-ray structure of the PGT domain of A. aeolicus PBP1A (aaPGT) from the n-MmA co-complex (PDB code 3D3H) (7−10). Since moenomycin is much larger than a typical molecule used in docking (1200 vs 350 Da) and has more rotatable bonds than can be currently handled by the Schrödinger Suite, we used CEF trisaccharide fragments rather than the full pentasaccharide for docking (Figure 4 , panels b, d, and f) (for sugar notation, see Figure 1 ). To validate the computational methods, we first confirmed that the docking results for the n-MmA CEF trisaccharide fragment were consistent with the crystal structure. The rmsd between the docked ligand and the ligand in the crystal structure of the complex was 1.1 Å, a very good agreement considering the large size of the docked ligand and the number of rotatable bonds. The docking computations were then extended to the CEF trisaccharide fragments of compounds 5 and 6 ( Figure 4 , panel d and f). Both docked in the same location as 2. We used the Glide 4.0 XP scoring function to estimate proteinϪ ligand binding affinities. This function incorporates unique water desolvation energy terms, hydrophobic enclosure, neutralϪneutral single or correlated hydrogen bonds, and five categories of chargedϪcharged hydrogen bonds (41) . The Glide scores for the trisaccharide fragments of 2, 5,and 6 were Ϫ12, Ϫ10.6, and Ϫ9.2, respectively, an order consistent with the relative affinities of the compounds based on the IC 50 measurements (42) . The RMSDs between n-MmA in the crystal structure and the docked trisaccharide analogues of 5 and 6 were 1.3 and 2.7 Å, respectively.
We redocked the CEF trisaccharide frgments of compounds 5 and 6 using restraints obtained from the X-ray data for the parent compounds (5 and 6; see Methods). Although the occupancy in the X-ray structures of the complexes is low, strong electron density corresponding to the phosphate atoms is clearly visible and can be used as experimental constraints. A glide score of Ϫ11.2 was obtained for the CEF trisaccharide fragment of compound 5 in the restrained docking compu- tations; the rmsd compared to n-MmA was 1.4 Å, similar to the rmsd from unrestrained docking computations. A score of Ϫ9.6 and an rmsd of 2.6 Å were obtained for the CEF trisaccharide fragment of compound 6, which is also similar to the rmsd from the unrestrained docking computations. It is notable that the neryl side chains in the docked structures of 2, 5, and 6 are oriented differently, suggesting that having the correctly positioned phosphoglycerate moiety also helps orient the lipid chain.
On the basis of the restrained docking computations, the high resolution X-ray structure of 2 complexed to the A. aeolicus PGT, and the IC 50 values of the analogues we have synthesized, we propose that the carboxylate of moenomycin plays an important role in binding through a favorable electrostatic interaction with an invariant lysine in the active site. This contact is observed in two of the four reported moenomycin:PGT complexes (see Figure 2 , panels b and e) (7−10). There may be a number of explanations for its absence in the other two complexes (7−10), including differences in crystallization conditions and the possibility that nonspecific hydrophobic interactions with the moenocinyl chain lead to misalignment of other functional groups. In any event, the relative activities of the descarboxyl analogues 4 and 6, the carboxamide 7, and the acylsulfonamide analogue 34 compared to those of the parent compounds clearly implicate the carboxylate negative charge in target binding.
Potential of Moenomycin As a Starting Point for Design of Clinically Useful Antibiotics. The PGTs are unexploited targets in the pathway for peptidoglycan biosynthesis. They are considered promising antibacterial targets because their structures are conserved, their functions are essential, they have no eukaryotic counterparts, and they are located on the external surface of the cytoplasmic membrane where they are accessible to molecules that cannot penetrate into the cell. The moenomy- cins are the only blueprints to guide the design of analogues, and it is important to understand in detail how they bind. Although recent high resolution structures have provided detailed information on proteinϪligand contacts, the importance of the contacts must be evaluated experimentally, particularly since there are some discrepancies. In this paper, we have focused on the role of the phosphoglycerate portion of moenomycin in binding to the PGT targets. Using a previously described method, we have been able to remove the phosphoglycerate lipid from the protected natural product and reattach a range of other phospholipids. We have prepared six different analogues of moenomycin containing changes to the phosphoglycerate-lipid portion of the molecule. On the basis of their enzyme inhibitory activity in conjunction with X-ray structural analysis and molecular docking, we have concluded that both the phosphoryl group and the carboxylate moiety of moenomycin form functionally important electrostatic interactions with conserved active site residues in the PGTs. The phosphate-protein contacts are similar in all four complexes and these contacts, shown in Figure 2 , likely explain the importance of the phosphoryl group in anchoring moenomycin in the active site. In contrast, the carboxylate-protein contacts vary in the complexes, with two showing a salt bridge to an invariant lysine and the others showing no attractive interactions. Studies on our synthetic analogues support the importance of the observed salt bridge.
An interesting observation is that the relative importance of both the phosphoryl group and the carboxylate depends on the length of the lipid chain. No decrease in enzyme inhibitory activity was observed when either one of these groups was modified in the context of the C25 chain (compare 1 to 3 or 4) ; in contrast, decreases of 2 to 3 orders of magnitude were observed when they were modified in the context of a C10 chain (compare 2 to 5, 6, 7, or 34). The results indicate that both the hydrophobic chain and the phosphoglycerate play a role in binding. One may contribute more to the energetics and the other may contribute more to the specificity. The C25 lipid clearly plays a major role in the biological activity of the natural product and probably contributes to target binding both by direct interactions with the hydrophobic funnel that leads to the membrane and by membrane anchoring. At the same time, it is also credited with the poor pharmacokinetic properties and high serum binding of moenomycin, so reducing its size is desirable. Although the C10 analogues are too short to retain biological activity, the C25 chain is longer than required for activity (43) . An optimal lipid length has not yet been identified, but one implication of the work reported here is that any reduction in the size of the lipid chain increases the importance of maintaining appropriate polar active site contacts.
METHODS
Materials. Radiolabeled heptaprenyl-Lipid II was synthesized as described by Ye et al. (36) . Moenomycin A (1) was extracted and purified from the feed stock flavomycin and purified as described (11) . n-MmA (2) was synthesized as previously described (11) . The synthesis and characterization of compounds 3Ϫ7 and 34 are described in Supporting Information. All other reagents and buffer components were purchased from SigmaAldrich.
Biological Activity Evaluation. IC 50 's against PBP2 from S. aureus and PBP2A from E. faecalis were obtained using a previously described assay (36, 37) . PBP2 from S. aureus and PBP2A from E. faecalis were prepared as described in refs 11, 34, and 35. MIC values (g mL
Ϫ1
) against laboratory strains of S. aureus and E. faecalis were obtained using the standard broth microdilution assay (44) . The MIC is defined as the lowest antibiotic concentration that resulted in no visible growth after incubation at 37°C for 22 h.
Crystallization and Structural Determination. Crystals of protein aaPGT (PBP1A[51Ϫ243]) were obtained as described previously (45) . Compounds 5 and 6 were soaked into PGT crystals at a concentration of 1 and 5 mM, respectively, in a stabilizing solution containing 100 mM HEPES, pH 7.5, 15% poly(ethylene glycol) 6000 (w/v) for 10 h. The crystals then were cryoprotected with 25% glycerol (v/v) and flash frozen in liquid nitrogen.
Data sets for two co-complexes were collected at NE-CAT beamline ID-24-C of the Advanced Photon Source (Argonne National Laboratories, Chicago). Data were indexed, integrated, and scaled with HKL2000 (46) , and the data collection statistics are shown in Supplementary Table S1 . The unit cell parameters for both co-complexes were very similar to the apo-aaPGT crystals, and therefore we placed the aaPGT coordinates (PDB code 2OQO) in the unit cell and refined the initial position by a rigid body protocol in CNS 1.225 (47) . The protein model in each complex was then further improved by several iterative rounds of manual fitting in COOT 0.326 (48) and cycles of simulated annealing and temperature factor refinement in CNS. Inspection of final 2f o Ϫ f c and f o Ϫ f c electron density maps confirmed the presence of ligand and the position of the phosphorus atoms. Detailed statistics pertaining to the final model are given in Supplementary Table S1 .
Structure-Based Docking. Protein structure-based docking was performed with the Schrödinger Suite (www.schrodinger. com). The coordinates of a complex of the peptidoglycan glycosyltransferase domain from A. aeolicus and n-MmA (PDB code 3D3H) were first optimized using Protein Preparation Wizard. As part of this step we added hydrogen atoms, stripped water mol- ecules, and performed energy minimization. The prepared coordinates were then used to calculate three grids, all centered at x ϭ 34.2 Å, y ϭ 34.2 Å, and z ϭ 10.3 Å. The first grid did not incorporate any restraints and was subsequently used for docking the CEF trisaccharide fragments of n-MmA. The other two grids were calculated to dock the CEF trisaccharide fragments of compounds 5 and 6, respectively, and therefore included positional restraints that would force the phosphorus atoms of the moenomycin derivatives to overlap, within 1.2 Å, with the position of the phosphorus atoms in the herein described X-ray structures. All ligands were prepared by the Schrödinger Ligprep module, and structure-based docking was performed with Glide version 50111 in the extra precision (XP) mode. The rootmean-square deviation was calculated for atoms in rings E and F and the phosphoglycerate group.
Accession Codes: The coordinates and structure factors have been deposited in the Protein Data Bank with PDB ID code 3NB6 (compound 5:aaPGT) and 3NB7 (compound 6:aaPGT).
